AstraZeneca PLC
AZNHealthcare|Drug Manufacturers - General|UK
$202.83
-0.66 (-0.32%)
DCF (FCF)
$71.68
Earnings Power
$36.18
About
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Stock Price
+34.5%(1Y)
Pipeline Summary
504 total trials153
Phase 1
107
Phase 2
95
Phase 3
39
Phase 4
Recruiting: 39NOT_YET_RECRUITING: 10Terminated: 41Withdrawn: 11Completed: 351Active: 33Unknown: 17ENROLLING_BY_INVITATION: 1APPROVED_FOR_MARKETING: 1
Active Trials (72)
The Eplontersen Pregnancy and Lactation Outcomes Study
NCT07205666Transthyretin Amyloidosis
Recruiting
Enrollment: 10 participants
PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults
NCT06981169Asthma
Recruiting
Enrollment: 1,500 participants
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis
Recruiting
Enrollment: 1,850 participants
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
Recruiting
Enrollment: 4,490 participants
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853Hormone-Sensitive Prostate Cancer
Phase 3Active
Enrollment: 1,012 participants
BioScore
6.2/10
Watchlist
Ownership
Recent News
2026-04-02 19:51:38
2026-04-02 12:00:03
2026-04-02 10:50:39
2026-04-02 10:26:18
2026-03-31 11:32:35
Data last updated: Apr 7, 2026, 01:27 PM